Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Exclusion Criteria

• •1. Pregnant women, breastfeeding women, or male and female subjects who do not agree to contraception during the 12 months before and after medication
• •2. Subjects with narrow anterior chamber angles or any other medical conditions that contraindicate pupil dilation
• •3. Subjects allergic to corticosteroids, who are unable to tolerate the corticosteroid treatment described in the protocol, or have active 4. concurrent infections that contraindicate treatment
• •4. Subjects with systemic diseases, or other medical or mental illnesses, or other safety concerns for the study
• •5. Subjects with other symptoms and/or diseases or conditions that can alter visual function, including but not limited to glaucoma and central nervous system lesions (mild cataracts are not included in this restriction)
• •6. Eye diseases that may interfere with the assessment of vision during the study and/or interfere with other ocular assessments such as OCT
• •7. Diseases that may affect the clinical trial, such as tumors, metabolic, immune-related diseases, etc.
• •8. Subjects who have undergone major eye surgery within the last 3 months before screening
• •9. Subjects with a history of malignant tumors within the last 5 years
• •10. Subjects with other retinal diseases not suitable for this study, such as retinal detachment
• •11. Patients undergoing or potentially undergoing immunosuppressive treatment for other diseases, excluding this study
• •12. Participation in any clinical trials other than this study within the last 3 months
• •13. Subjects who have received gene therapy outside of this study
• •14. Other reasons deemed by the researcher as unsuitable for participation in this study